INDOCO vs WOCKPHARMA: Stock Comparison

Indoco Remedies Limited vs Wockhardt Ltd

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Indoco Remedies Limited shows a lower P/E and a higher dividend yield, while Wockhardt Ltd shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Indoco Remedies Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, INDOCO is more favourable on 3 of 13 scored metrics and WOCKPHARMA on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹2,160 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 144.46x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 6.23x
EPS
WOCKPHARMA has higher earnings per share
₹13.1 vs ₹-10.71
Dividend Yield
INDOCO has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 21.9%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs 21.9%
Qtr Profit Growth
WOCKPHARMA has stronger quarterly profit growth
688% vs 39%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOWOCKPHARMA
Live Price₹233.99₹1,869
Day Change-4.82%-1.44%
Volume71,6887.07 L
52-Week High₹336₹2,422.3
52-Week Low₹162.19₹1,086.7
Distance from 52W High-30.36%-22.84%

Valuation

MetricINDOCOWOCKPHARMA
Market Cap₹2,160 Cr₹30,362 Cr
P/E Ratio-23.83x144.46x
P/B Ratio2.41x6.23x
EPS₹-10.71₹13.1
Book Value₹111.55₹304
Dividend Yield0.08%0%

Growth

MetricINDOCOWOCKPHARMA
Revenue Growth (TTM YoY)21.9%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth21.9%29.9%
Qtr Profit Growth39%688%

Profitability & Leverage

MetricINDOCOWOCKPHARMA
ROE-9.42%6.11%
ROCE0.93%7.55%
Net Margin-5.31%3.3%
Operating Margin7.68%19.3%
Debt to Equity1.16x0.45x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOWOCKPHARMA
Promoter Holding58.86%49.08%
FII Holding1.27% 0.33 pp7.09% 0.1 pp
DII Holding17.68% 0.47 pp10.96% 0.41 pp
Public Holding22.04% 0.14 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Indoco Remedies Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.